| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.19 | 0.002 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |